Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CORT, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Mifepristone FDA approved Feb 2012 · Korlym |
Hypercortisolism | Phase 4 · NCT05772169 | Completed |
| Relacorilant (CORT125134) FDA approved Mar 2026 · Lifyorli (Copackaged) |
Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 · NCT04329949 | Terminated |
| Nab-paclitaxel | Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 · NCT04329949 | Terminated |
| Nenocorilant | Neoplasms | Phase 1/2 · NCT07276373 | Recruiting |
| Miricorilant (CORT118335) | Antipsychotic-induced Weight Gain (AIWG) | Phase 2 · NCT03818256 | Completed |
| TPC | Metastatic Breast Cancer | Phase 2 · NCT06099769 | Recruiting |
| Exicorilant | Metastatic Castration-Resistant Prostate Cancer | Phase 1/2 · NCT03437941 | Terminated |
| Dazucorilant | Amyotrophic Lateral Sclerosis | Phase 2 · NCT05407324 | Active not recruiting |
| CORT113176 Lipid Capsule Formulation | Healthy Adults | Phase 1 · NCT04249323 | Completed |
| CORT113176 | Healthy Adults | Phase 1 · NCT04994743 | Completed |
| [14C]-CORT113176 | Healthy | Phase 1 · NCT04990310 | Completed |
| CORT125236 | Healthy | Phase 1 · NCT05003713 | Completed |
| CORT125329 lipid capsule formulation | Healthy | Phase 1 · NCT04672512 | Completed |
| Moxifloxacin | Healthy | Phase 1 · NCT04795479 | Completed |
| Fluvoxamine | Antipsychotic Induced Weight Gain | Phase 1 · NCT05712265 | Completed |
Also used in these trials (approved or third-party drugs, not CORT's own candidates): Bevacizumab, Nivolumab, Gemcitabine Hydrochloride, Enzalutamide, Olanzapine, Pembrolizumab, Prednisone, Dabigatran Etexilate, Risperidone, Itraconazole.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CORT holds $544.6M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CORT files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Blackrock Inc. | Institution (13F) | 12,432,023 | 11.50% | 2026-06-30 |
| INGALLS & SNYDER LLC | Institution (13G, 5%+) | 7,263,466 | 6.72% | 2025-12-31 |
| G Leonard Jr Baker Director · +12,500 options |
Insider | 5,550,196 | 5.13% | 2026-03-17 |
| Renaissance Technologies, LLC | Institution (13F) | 5,261,628 | 4.87% | 2026-06-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 5,044,638 | 4.67% | 2026-06-30 |
| Vanguard Capital Management LLC | Institution (13F) | 4,172,482 | 3.86% | 2026-06-30 |
| Parallel Advisors, LLC | Institution (13F) | 3,962,177 | 3.67% | 2026-06-30 |
| FMR, LLC | Institution (13F) | 3,337,618 | 3.09% | 2026-06-30 |
| State Street Corporation | Institution (13F) | 3,279,381 | 3.03% | 2026-06-30 |
| Joseph K Belanoff Chief Executive Officer, Director · +460,000 options |
Insider | 2,865,489 | 2.65% | 2026-05-29 |
| AQR Capital Management, LLC | Institution (13F) | 2,582,561 | 2.39% | 2026-06-30 |
| Geode Capital Management, LLC | Institution (13F) | 2,532,198 | 2.34% | 2026-06-30 |
Share count 108,098,397 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-09-24 filed 2026-09-28 |
Robb Gary Charles |
Gift (G) | 17,100 | – | 14,056 |
| 2026-09-24 filed 2026-09-28 |
Robb Gary Charles |
Gift (G) | 5,000 | – | 20,571 |
| 2026-09-17 filed 2026-09-18 |
Robb Gary Charles |
Option exercise (M) | 17,493 | $8.27 | 31,156 |
| 2026-09-17 filed 2026-09-18 |
Robb Gary Charles |
Option exercise (M) | 17,493 | – | – |
| 2026-09-16 filed 2026-09-18 |
Vieira Roberto Wandenkolk |
Sale (S) | 296 | $100.82 | 3,946 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-07-11 | Relacorilant | NDA | +18.6% | — | — |
| 2025-12-31 | — | NDA | -11.6% | -50.4% | -47.3% |
| 2025-12-30 | relacorilant | NDA | +0% | -12.1% | -55.2% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CORT and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →